Novo Nordisk A/S (ADR) (NVO) was Upgraded by Exane BNP Paribas to ” Outperform”. Earlier the firm had a rating of “Neutral ” on the company shares. Exane BNP Paribas advised their investors in a research report released on Sep 13, 2016.
Many Wall Street Analysts have commented on Novo Nordisk A/S (ADR). Novo Nordisk A/S (ADR) was Downgraded by JP Morgan to ” Neutral” on Sep 9, 2016. Novo Nordisk A/S (ADR) was Downgraded by Morgan Stanley to ” Equal-Weight” on Sep 1, 2016. Novo Nordisk A/S (ADR) was Upgraded by HSBC Securities to ” Hold” on Aug 31, 2016.
Novo Nordisk A/S (ADR) opened for trading at $44.76 and hit $46.24 on the upside on Monday, eventually ending the session at $46.1, with a gain of 4.68% or 2.06 points. The heightened volatility saw the trading volume jump to 4,492,616 shares. Company has a market cap of $119,860 M.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery development manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins GLP-1 other protein-related products (such as glucagon protein-related delivery systems and needles) oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark and internationally in the United States France China and Brazil.